389030.Kq
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.
Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.
The company has a high price-to-book ratio of 14.64, indicating that the market values the company significantly above its book value. The price-to-tangible-book ratio is also 14.64, suggesting that intangible assets are a major component of the company's valuation. The company's debt-to-equity ratio is 1.0, indicating that the company has a balanced capital structure with equal amounts of debt and equity. The current ratio of 0.77 suggests that the company may have some liquidity challenges, as its current assets are less than its current liabilities.
The company's profitability metrics are concerning, with a negative return on equity of -1.9088 and a negative return on assets of -0.4415. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at -11,671,177,570, and the net income is also negative at -17,373,136,630, highlighting the company's current financial difficulties.
The company's revenue is concentrated in a single segment, as there are no disclosed segments in the financial data. The geographic exposure is not specified, but the company's operations are likely focused in a specific region given the lack of detailed geographic breakdown. The company's revenue concentration may pose a risk if the market or regulatory environment in that region changes.
The company's growth trajectory is uncertain, as the financial data does not provide specific outlook figures for the current or next fiscal year. The company's operating cash flow is negative at -7,079,975,050, and the free cash flow is also negative at -15,511,289,300, indicating that the company is not generating sufficient cash to fund its operations or growth initiatives.
The company faces medium liquidity risk, as indicated by the risk assessment. The key flag of negative net cash after subtracting total debt suggests that the company may need to raise additional capital or restructure its debt to maintain operations. The dilution risk is low, but the company's negative free cash flow and high debt levels may necessitate future equity issuances, which could dilute existing shareholders.
Recent events and filings have not been disclosed in the provided data, so there is no information available on recent developments that may impact the company's financial position or strategic direction.
- The company has a high price-to-book ratio, indicating that the market values the company significantly above its book value.
- The company's profitability metrics are negative, with a return on equity of -1.9088 and a return on assets of -0.4415.
- The company's capital structure is balanced with a debt-to-equity ratio of 1.0, but it faces liquidity challenges with a current ratio of 0.77.
- The company's growth trajectory is uncertain, as it is not generating sufficient cash flow to fund operations or growth initiatives.
- The company faces medium liquidity risk and may need to raise additional capital or restructure its debt to maintain operations.
- "margin_outlook_rationale": "The company's margin outlook is negative due to its current financial difficulties, as indicated by its negative operating and net income.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 389030.KQ Market data — financials · 2026-05-26